Literature DB >> 25789811

Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.

Soley Bayraktar1, Michelle Jackson, Angelica M Gutierrez-Barrera, Diane Liu, Funda Meric-Bernstam, Amanda Brandt, Ashley Woodson, Jennifer Litton, Karen H Lu, Vicente Valero, Banu K Arun.   

Abstract

The genotype-phenotype correlations of the specific BRCA1 and BRCA2 mutations in multi-ethnic populations in USA have not yet been fully investigated. This study was designed to evaluate the effects of ethnicity at specific mutation locations and breast/ovarian cancer phenotypes. Our cohort included 445 women with different ethnic backgrounds who underwent BRCA genetic testing between 1997 and 2010. Known clinical and pathologic characteristics were compared with Chi-Square Analysis or Fisher's Exact test as appropriate. The three most common mutation locations in BRCA1 (exons 2, 11, and 20) and BRCA2 (exons 10, 11, and 25) genes were chosen. Prevalence of BRCA1 exon 2 mutations were significantly higher in Ashkenazi Jewish (AJ) women compared to Caucasians (41% versus 15%; p = 0.001). Similarly, AJ women with breast cancer were more likely to have BRCA1 exon 2 mutation (47% positivity in AJ women versus 0-12.5% positivity in other ethnicities; p = 0.004). Women carrying the exon 20 BRCA1 mutation had the highest probability of having combined breast and ovarian cancers compared to women carrying other exon mutations (p = 0.05). The median age at initial cancer diagnosis, phenotypic features of breast cancer tumors, and overall survival did not vary significantly by ethnicity or mutation location. Our data suggest that ethnicity does not affect age of onset, overall survival or confer different risks of breast and ovarian cancer development in BRCA carriers. These results also suggest that women carrying the exon 20 BRCA1 mutation may warrant mutation-specific counseling and be more aggressively managed for risk reduction.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  BRCA1; BRCA2; breast cancer; ethnicity; mutation location; ovarian cancer

Mesh:

Substances:

Year:  2015        PMID: 25789811      PMCID: PMC5411012          DOI: 10.1111/tbj.12392

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  28 in total

1.  The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data.

Authors:  A Y Bahar; P J Taylor; L Andrews; A Proos; L Burnett; K Tucker; M Friedlander; M F Buckley
Journal:  Cancer       Date:  2001-07-15       Impact factor: 6.860

Review 2.  Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families.

Authors:  P Tonin; B Weber; K Offit; F Couch; T R Rebbeck; S Neuhausen; A K Godwin; M Daly; J Wagner-Costalos; D Berman; G Grana; E Fox; M F Kane; R D Kolodner; M Krainer; D A Haber; J P Struewing; E Warner; B Rosen; C Lerman; B Peshkin; L Norton; O Serova; W D Foulkes; J E Garber
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

3.  Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.

Authors:  B Modan; P Hartge; G Hirsh-Yechezkel; A Chetrit; F Lubin; U Beller; G Ben-Baruch; A Fishman; J Menczer; J P Struewing; M A Tucker; S Wacholder
Journal:  N Engl J Med       Date:  2001-07-26       Impact factor: 91.245

4.  Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.

Authors:  Jeffrey N Weitzel; Jessica Clague; Arelis Martir-Negron; Raquel Ogaz; Josef Herzog; Charité Ricker; Chelsy Jungbluth; Cheryl Cina; Paul Duncan; Gary Unzeitig; J Salvador Saldivar; Mary Beattie; Nancy Feldman; Sharon Sand; Danielle Port; Deborah I Barragan; Esther M John; Susan L Neuhausen; Garrett P Larson
Journal:  J Clin Oncol       Date:  2012-12-10       Impact factor: 44.544

5.  Variation in BRCA1 cancer risks by mutation position.

Authors:  Deborah Thompson; Douglas Easton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-04       Impact factor: 4.254

6.  Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases.

Authors:  K E Malone; J R Daling; C Neal; N M Suter; C O'Brien; K Cushing-Haugen; T J Jonasdottir; J D Thompson; E A Ostrander
Journal:  Cancer       Date:  2000-03-15       Impact factor: 6.860

7.  Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

Authors:  Deann P Atchley; Constance T Albarracin; Adriana Lopez; Vicente Valero; Christopher I Amos; Ana Maria Gonzalez-Angulo; Gabriel N Hortobagyi; Banu K Arun
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

8.  Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.

Authors:  William D Foulkes; Kelly Metcalfe; Ping Sun; Wedad M Hanna; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Olufunmilayo I Olopade; Barbara L Weber; Jane McLennan; Ivo A Olivotto; Louis R Bégin; Steven A Narod
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

9.  Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation.

Authors:  S A Gayther; W Warren; S Mazoyer; P A Russell; P A Harrington; M Chiano; S Seal; R Hamoudi; E J van Rensburg; A M Dunning; R Love; G Evans; D Easton; D Clayton; M R Stratton; B A Ponder
Journal:  Nat Genet       Date:  1995-12       Impact factor: 38.330

10.  Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Authors:  Timothy R Rebbeck; Susan M Domchek
Journal:  Breast Cancer Res       Date:  2008-07-25       Impact factor: 6.466

View more
  8 in total

1.  Genotype-Phenotype Correlation in Indian Patients with MEN2-Associated Pheochromocytoma and Comparison of Clinico-Pathological Attributes with Apparently Sporadic Adrenal Pheochromocytoma.

Authors:  Sendhil Rajan; Ghazala Zaidi; Gaurav Agarwal; Anjali Mishra; Amit Agarwal; Saroj Kanta Mishra; Eesh Bhatia
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

2.  BRCA testing and outcomes in women with breast cancer.

Authors:  David D Stenehjem; Claire Telford; Sudhir K Unni; Hillevi Bauer; Amy Sainski; Rishi Deka; Marisa B Schauerhamer; Xiangyang Ye; Casey R Tak; Junjie Ma; Tapashi B Dalvi; Lia Gutierrez; James A Kaye; Jerzy E Tyczynski; Diana I Brixner; Joseph E Biskupiak
Journal:  Breast Cancer Res Treat       Date:  2021-01-03       Impact factor: 4.872

3.  Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study.

Authors:  Muhammed Mustafa Atcı; Çağlayan Geredeli; Seval Ay; Abdullah Sakin; Biray Ertürk; Şaban Seçmeler; Serdar Arıcı; Ruhper Çekin; Nurgül Yaşar; Orçun Can; Şener Cihan; Mahmut Gümüş
Journal:  Eur J Breast Health       Date:  2021-03-31

4.  BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients.

Authors:  Lorena Incorvaia; Daniele Fanale; Marco Bono; Valentina Calò; Alessia Fiorino; Chiara Brando; Lidia Rita Corsini; Sofia Cutaia; Daniela Cancelliere; Alessia Pivetti; Clarissa Filorizzo; Maria La Mantia; Nadia Barraco; Stefania Cusenza; Giuseppe Badalamenti; Antonio Russo; Viviana Bazan
Journal:  Ther Adv Med Oncol       Date:  2020-12-16       Impact factor: 8.168

5.  Family specific genetic predisposition to breast cancer: results from Tunisian whole exome sequenced breast cancer cases.

Authors:  Yosr Hamdi; Maroua Boujemaa; Mariem Ben Rekaya; Cherif Ben Hamda; Najah Mighri; Houda El Benna; Nesrine Mejri; Soumaya Labidi; Nouha Daoud; Chokri Naouali; Olfa Messaoud; Mariem Chargui; Kais Ghedira; Mohamed Samir Boubaker; Ridha Mrad; Hamouda Boussen; Sonia Abdelhak
Journal:  J Transl Med       Date:  2018-06-07       Impact factor: 5.531

6.  Mutation Frequencies in Endometrial Cancer Patients of Different Ethnicities and Tumor Grades: An Analytical Study.

Authors:  Mohammad A Althubiti
Journal:  Saudi J Med Med Sci       Date:  2018-12-14

7.  BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients.

Authors:  Michalis Liontos; Eleni Zografos; Panagiotis Zoumpourlis; Angeliki Andrikopoulou; Anna Svarna; Oraianthi Fiste; Elena Kunadis; Alkistis Maria Papatheodoridi; Maria Kaparelou; Konstantinos Koutsoukos; Nikoloas Thomakos; Dimitrios Haidopoulos; Alexandros Rodolakis; Meletios-Athanasios Dimopoulos; Flora Zagouri
Journal:  Curr Oncol       Date:  2021-11-03       Impact factor: 3.677

8.  CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.

Authors:  Josephine B Walton; Malcolm Farquharson; Susan Mason; Jennifer Port; Bjorn Kruspig; Suzanne Dowson; David Stevenson; Daniel Murphy; Martin Matzuk; Jaeyeon Kim; Seth Coffelt; Karen Blyth; Iain A McNeish
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.